SUBSCRIBE: Print / eNewsletter
Newer Strategies for the Management of Low-Grade Gliomas
Given the longer course and natural history of low-grade gliomas, the goals of treatment should be to prolong overall survival and minimize neurocognitive decline.
Local Control of Brain Mets Improved With Stereotactic Radiosurgery
Patients with resected brain metastases who underwent stereotactic radiosurgery had lower rates of local recurrence compared with observation alone, according to the results of a phase III trial.
Optical Technology Detects Cancer With High Accuracy During Surgery
An intraoperative, multimodal optical cancer detection system can detect brain cancer with high degrees of accuracy, sensitivity, and specificity in real time during surgery, according to a new study.
FDA Approves Fluorescing Agent for Glioma Surgery
The US Food and Drug Administration has approved the optical imaging agent aminolevulinic acid hydrochloride to enhance visualization of malignant tissue during surgery for gliomas.
Peptide Vaccine Shows Clinical Benefit in Glioblastoma
A personalized peptide vaccination shows clinical benefit for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.
Managing Glioblastoma in the Elderly Patient: New Opportunities
This review discusses best practices for the treatment of glioblastoma in patients older than 65 years, and highlights management concerns in caring for this particular patient population.
HER2-Specific CAR T-Cell Therapy Active in Progressive Glioblastoma
Administration of autologous HER2-specific CAR-modified virus specific T Cells was safe and had clinical benefit for some patients with progressive glioblastoma, a disease with limited effective therapeutic options.
Vaccines to Prevent High-Grade Glioma
This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.
Vaccine/Chemotherapy Combination Improves Survival in Glioblastoma
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma.
Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma
This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.